INCI
INCI NAMEv2.0
enkozhja
原料辞典検索/palmitoyl-tripeptide-1/PALMITOYL TRIPEPTIDE-1
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
ペプチド・タンパク質 (Peptide)

PALMITOYL TRIPEPTIDE-1

標準 INCI 準拠: PALMITOYL TRIPEPTIDE-1
皮膚コンディショニング剤
[EU CosIng Official Definition] Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における PALMITOYL TRIPEPTIDE-1 のグローバル配合基準と処方特性とは？

PALMITOYL TRIPEPTIDE-1（CAS番号: 147732-56-7）は、化粧品処方において主に皮膚コンディショニング剤として配合される原料です。日本厚労省/JCIA（規制なし）、韓国MFDS（規制なし）、欧州CosIng（規制なし）など6大法域の法定基準下で管理され、通常 0.001–0.15%（適正安定域 pH 4.5–7.5）で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for PALMITOYL TRIPEPTIDE-1
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)PALMITOYL TRIPEPTIDE-1 (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)Former KR Nomenclature Redirect Active—
③ 欧州連合 (EU CosIng EC 1223/2009)PALMITOYL TRIPEPTIDE-1
④ 米国一般化粧品 (US PCPC / MoCRA INCI)PALMITOYL TRIPEPTIDE-1
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)棕榈酰三肽-1
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)PALMITOYL TRIPEPTIDE-1 (標準INCI参照 · 任意カタカナ音訳排除)

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for PALMITOYL TRIPEPTIDE-1
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #8747
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for PALMITOYL TRIPEPTIDE-1
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
中国 IECIC 最高歴史使用量leave_on≤ 0.2%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 08941 (2025)
中国 IECIC 最高歴史使用量rinse_off≤ 0.1%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 08941 (2025)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Emulsion / Creamn=58
Min 0.001% · Q1 0.005% · Median 0.01% · Q3 0.05% · Max 0.15%
Emulsion / Cream — Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis
Verified Source: Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment (cir_safety) · Sederma/Croda 44 · Evonik 14
Typical Median: 0.01%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for PALMITOYL TRIPEPTIDE-1
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 B — 乳液・エマルジョン・クリーム0.001% · 0.005% · 0.01% · 0.05% · 0.15%Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesisSederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment
Cutaneous Permeation Science (500 Dalton Rule)MW: 578.8 Da · LogP: 2.8

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesBio-Spicule Micro-Needle (180–250 µm)Physical Micro-Channel ConduitDermal Delivery (~14.2x Flux)
Molecular Weight & LogP Permeation Diagnosis
Macromolecule (578.8 Da > 500 Da) — Transdermal Booster Required

Co-formulating with 0.1–0.5% Hydrolyzed Sponge (Bio-Spicule, 180–250 µm) creates transient micro-channels across the stratum corneum, delivering actives directly into the papillary dermis (PMID: 34112845).

Estimated Target Depth
180–250 µm
Optimal Delivery System
Bio-Spicule + Liposome
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Soluble in glycols/surfactant premixes (supplied as 100~1000 ppm solution)
Optimal Formulation pH Stability Window (0–14)pH 4.5 – 7.5
0245.5791114

Outside pH 4.5–7.5, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ PALMITOYL TETRAPEP…+ RETINOL+ CERAMIDE NP+ NIACINAMIDE✕ Palmitoyl C16 tail e…PALMITOYL TRIPEPTI…
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

+ PALMITOYL TETRAPEPTIDE-7+ RETINOL+ CERAMIDE NP+ NIACINAMIDE
代表商品名参考 (商標法第90条第1項第2号 記述的表示)
Matrixyl® 3000 (with Palmitoyl Tetrapeptide-7)Biopeptide CL™

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: PALMITOYL TRIPEPTIDE-1 | CAS No.: 147732-56-7 | EC No.: N/A - Origin: PEPTIDE | Functions: Skin Conditioning - Physicochemical Profile: Formula C30H54N6O5 | MW 578.8 g/mol | LogP 2.8 | Ionic Nature: amphoteric | PubChem CID 9862849 - Official Regional Label Names: US [PALMITOYL TRIPEPTIDE-1] · EU [PALMITOYL TRIPEPTIDE-1] · CN [棕榈酰三肽-1] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1 Classified under origin 'peptide', it acts within the cosmetic vehicle or stratum corneum to deliver performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 8747 (棕榈酰三肽-1)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 0.2% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 0.1% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 0.001 ~ 0.15% (Median 0.01%, Ref: Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment) — Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.5 ~ 7.5 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C - Synergy Pairings: PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE | Reference Trade Names: Matrixyl® 3000 (with Palmitoyl Tetrapeptide-7), Biopeptide CL™ ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 41527525 (2026, J Cosmet Dermatol): Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism

関連査読付き学術論文 (NIH PubMed) (1)

Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism [PMID: 41527525 · 2026]
Wang C, Song T, Zhang Y, Li N, Xie L, Xie M, Jiang X, L&#xfc; G, Meng Y, Wang C, Yue L, Yang W, Li Y, Wu Y, Chen L · J Cosmet Dermatol (2026)

Collagen is essential for maintaining skin structure and function, and the circadian rhythm is known to regulate a wide range of physiological processes. To investigate whether collagen metabolism in human skin fibroblasts exhibits circadian regulation, and to evaluate whether the time-coordinated application of baicalin at daytime and palmitoyl tripeptide-1 (PT-1) at nighttime synergistically promotes collagen fiber formation and improves overall skin quality. A circadian-synchronized human skin fibroblast model was established. The expression of collagen metabolism-related genes was analyzed using qPCR and immunofluorescence. Subsequently, an 8-week topical application study was conducted in mice using a regimen of daytime baicalin and nighttime PT-1. Finally, a clinical trial involving 30 female participants was conducted, employing the same time-coordinated application scheme. Fibroblasts exhibited opposing day-night rhythms: genes for collagen assembly (e.g., LOX) peaked during the day, while those involved in synthesis/secretion (e.g., Sec61a2, Mia3, Pde4d, Vps33b) and degradation (e.g., CTSK, MMP1) peaked at night. Time phase-dependent interventions showed baicalin enhanced daytime assembly, while PT-1 boosted nighttime synthesis. In mice, a timed day-night combination therapy increased collagen fiber density. Clinical trial (n&#x2009;=&#x2009;30) confirmed the efficacy, showing significant improvements in skin luminance (+16.29%), nasolabial fold depth (-36.35%), and firmness (R2: +24.35%). Collagen metabolism is regulated by circadian rhythms. Chronomodulated baicalin and PT-1 application synergistically optimize collagen metabolism and improve skin quality.

よくある質問 (FAQ)

Q1. PALMITOYL TRIPEPTIDE-1 の各国公式全成分表示名称（7トラック）はどのように異なりますか？
日本化粧品工業連合会(JCIA)表示名称は 'PALMITOYL TRIPEPTIDE-1 (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'PALMITOYL TRIPEPTIDE-1'、中国NMPA IECIC標準中国語名は '棕榈酰三肽-1' です。
Q2. PALMITOYL TRIPEPTIDE-1 のグローバル6大法域における法定配合基準 (Layer 1) は？
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における PALMITOYL TRIPEPTIDE-1 の通常配合濃度 (Layer 3) と適正 pH は？
主要剤形 (emulsion_cream) において通常 0.001〜0.15%（中央値 0.01%）で配合され、適正pH範囲は 4.5〜7.5 です。
Q4. PALMITOYL TRIPEPTIDE-1 の配合禁忌 (Incompatibilities) と推奨シナジー成分は？
推奨シナジーペアは PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE、配合上の注意点は Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C です。